669
Participants
Start Date
January 2, 2017
Primary Completion Date
October 27, 2022
Study Completion Date
June 30, 2026
Durvalumab (MEDI4736)
Anti-PD-L1 monoclonal Antibody monotherapy
Paclitaxel + carboplatin
Chemotherapy Agents
Gemcitabine + cisplatin
Chemotherapy Agents
Gemcitabine + carboplatin
Chemotherapy Agents
Pemetrexed + cisplatin
Chemotherapy Agent
Pemetrexed + carboplatin
Chemotherapy Agent
Research Site, Taipei
Research Site, Taipei
Research Site, Taichung
Research Site, Budapest
Research Site, Budapest
Research Site, Budapest
Research Site, Törökbálint
Research Site, St Leonards
Research Site, Kogarah
Research Site, Gosford
Research Site, Box Hill
Research Site, Gyöngyös - Mátraháza
Research Site, Deszk
Research Site, Székesfehérvár
Research Site, Farkasgyepü
Research Site, Hanoi
Research Site, Ho Chi Minh City
Research Site, Bangkok
Research Site, Bangkok
Research Site, Suwon
Research Site, Pamukkale
Research Site, Incheon
Research Site, Cheongju-si
Research Site, Istanbul
Research Site, Istanbul
Research Site, Taichung
Research Site, Daegu
Research Site, Malatya
Research Site, Muang
Research Site, Changwon-si
Research Site, Ho Chi Minh City
Research Site, Songkhla
Research Site, Anaheim
Research Site, Hanoi
Research Site, Beijing
Research Site, Beijing
Research Site, Beijing
Research Site, Shenyang
Research Site, Moscow
Research Site, Changchun
Research Site, Arkhangelsk
Research Site, Saint Petersburg
Research Site, Saint Petersburg
Research Site, Saint Petersburg
Research Site, Saint Petersburg
Research Site, Saint Petersburg
Research Site, Shanghai
Research Site, Nanjing
Research Site, Bengbu
Research Site, Jinan
Research Site, Hangzhou
Research Site, Hangzhou
Research Site, Hangzhou
Research Site, Hangzhou
Research Site, Ningbo
Research Site, Linhai
Research Site, Nanchang
Research Site, Rostov-on-Don
Research Site, Chongqing
Research Site, Volgograd
Research Site, Wanzhou
Research Site, Changsha
Research Site, Wuhan
Research Site, Wuhan
Research Site, Wuhan
Research Site, Zhengzhou
Research Site, Guangzhou
Research Site, Guangzhou
Research Site, Zhuhai
Research Site, Haikou
Research Site, Chengdu
Research Site, Novosibirsk
Research Site, Omsk
Research Site, Ho Chi Minh City
Research Site, Xi'an
Research Site, Xi'an
Research Site, Ürümqi
Research Site, Ürümqi
Research Site, Can Tho
Research Site, Shijiazhuang
Research Site, Wenzhou
Research Site, Almelo
Research Site, Bialystok
Research Site, Grudziądz
Research Site, Koszalin
Research Site, Lublin
Research Site, Mrozy
Research Site, Warsaw
Research Site, Wroclaw
Research Site, Jinju
Research Site, Seoul
Research Site, Ankara
Lead Sponsor
AstraZeneca
INDUSTRY